Shire plc (JOBS): Non-Safety-Related Voluntary Recall of a Limited Portion of Daytrana(R) Patches Announced 12/3/2009
More...
|
American Academy of Pediatrics Nixes Heart Tests Before ADHD Drugs 7/30/2008
More...
|
GlaxoSmithKline Consumer Healthcare Release: Nicotine Replacement Therapy Is Safe, Effective and Can Help Reverse Mental Acuity Deficits in Smokers Who Are Quitting, Including Commercial and Private Pilots Commit 4 mg Lozenge Helps Reverse Symptoms Associated with Nicotine Withdrawal Including Difficulty Concentrating, Attention Deficit, Memory Deficit and Selective Attention Deficit 5/23/2008
More...
|
Abbott Laboratories (ABT) Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder Phase II Data 5/7/2008
More...
|
Cardiac Screening Recommended for Kids Taking Stimulants for ADHD 4/22/2008
More...
|
Effective ADHD Treatment Found For Children With Fragile X Syndrome 2/22/2008
More...
|
FDA Approves Additional Dosage Strengths of Shire Pharmaceuticals Group plc (SHPGY)'s ADHD Treatment VYVANSE(TM) 1/3/2008
More...
|
19% of ADHD Patients Get Too Many Drugs 12/7/2007
More...
|
Auriga Laboratories, Inc. (ARGA.OB) Obtains Rights to Market and Sell a New Product Indicated for the Treatment of ADHD 12/3/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD 11/30/2007
More...
|
Dore USA Ground Breaking Drug-Free Treatment for ADHD 11/29/2007
More...
|
Cogmed New Study Finds Working Memory Training Produces Lasting Improvements in Kids with Attention Deficits 11/29/2007
More...
|
Drugs for ADHD 'Not the Answer' 11/12/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Results of a Survey of Parents' Perceptions of the Duration of Their Child's ADHD Medication 11/9/2007
More...
|
Major U.S. Clinics Partner with Cogmed to Provide Computerized Training to Kids, Adults with Attention Problems 11/5/2007
More...
|
Sciele Pharma, Inc. (SCRX) and Addrenex Pharmaceuticals Announce Initiation of Pivotal Phase III Trials for Clonicel for ADHD 10/30/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting 10/29/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) 10/26/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting 10/25/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 10/23/2007
More...
|
FDA Rejects Cortex Pharmaceuticals, Inc. (COR)'s Request for Study of Drug Candidate 10/11/2007
More...
|
Gov't to Study Heart Risks of ADHD Drugs 9/18/2007
More...
|
Cortex Pharmaceuticals, Inc. (COR) Files AMPAKINE CX717 IND for ADHD 9/12/2007
More...
|
Bupropion Doesn't Prevent Smoking in ADHD Patients 8/30/2007
More...
|
New Study Suggests Non-Medication Treatment for Preschool ADHD Is Highly-Effective; Lehigh University's Research is ''Most Ambitious'' Ever 8/16/2007
More...
|
Gene Predicts Better Outcome as Cortex Normalizes in Teens with ADHD 8/7/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY)'s New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
7/27/2007
More...
|
Improvement Following ADHD Treatment Sustained in Most Children 7/23/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults 7/2/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD 6/21/2007
More...
|
Noven Pharmaceuticals Inc. (NOVN) & Shire Pharmaceuticals Group plc (SHPGY) to Develop New Transdermal Patch For ADHD 6/20/2007
More...
|
Eli Lilly and Company (LLY) Seeks Entries for Focus on Your Possibilities Adult ADHD Scholarship Program 6/15/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents 5/24/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) DAYTRANA(TM) (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls 5/24/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA(TM) (methylphenidate transdermal system) 5/24/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Study Suggests Strattera(R) Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse 5/24/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Long-term Treatment with VYVANSE(TM) (lisdexamfetamine dimesylate), the First Prodrug Stimulant, Demonstrates Significant Efficacy in Children with ADHD 5/24/2007
More...
|
McNeil Pediatrics New Data Suggests Less Abuse-Related Effects For OROS(R) Methylphenidate 5/23/2007
More...
|
FDA Issues Approvable Letter for Shire Pharmaceuticals Group plc (SHPGY)'s SPD465 for the Treatment of ADHD in Adults 5/21/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting 5/14/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD 5/3/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD 4/20/2007
More...
|
Massachusetts Institute of Technology (MIT) Neuroscientists Find Different Brain Regions Fuel Attention; Work Could Be Significant in Treatment of ADD 3/30/2007
More...
|
Study Shows Near Tripling of Global ADHD Drug Use 3/7/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) (Jobs) and New River Pharmaceuticals Inc. (NRPH) Announce FDA Approval of The First and Only Stimulant Prodrug VYVANSE(TM) as a Novel Treatment for ADHD 2/26/2007
More...
|
US FDA Tells ADHD Makers To Warn Patients Of Risks 2/21/2007
More...
|
Shire Pharmaceuticals Group plc (SHPGY) (Jobs) To Buy New River Pharmaceuticals Inc. (NRPH) For $2.6 Billion To Get Key Drug 2/20/2007
More...
|
New River Pharmaceuticals Inc. (NRPH) And Shire PLC Receive Approvable Letter For VYVANSE(TM) (lisdexamfetamine dimesylate) For The Treatment Of ADHD 12/22/2006
More...
|
Shire PLC Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17 11/17/2006
More...
|
Shire PLC Announces Results Of Its Bioequivalence Study Of SPD465, An Investigational Drug For Adults With ADHD 11/17/2006
More...
|
Shire PLC Announces Results Of A Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications In Treating ADHD in Patients Aged 8 to 15 11/17/2006
More...
|
ADHD Treatment Safe And Effective For Preschoolers 10/31/2006
More...
|
Shire Pharmaceuticals (SHPGY) Announces Study Results For Investigational Drug (SPD465) Designed To Reduce ADHD Symptoms For Up To 16 Hours 10/31/2006
More...
|
Shire PLC Release: DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management 10/27/2006
More...
|
Study Suggests Eli Lilly and Company (LLY)'s Strattera(R) Was Effective In Treating ADHD In Children And Adolescents With ADHD And Reading Disorders 10/27/2006
More...
|
McNeil Pediatrics New Study Supports Low Abuse Potential Of Leading ADHD Medication, CONCERTA(R) (methylphenidate HCl) 10/27/2006
More...
|
Eli Lilly and Company (LLY) Release: Study Suggests Strattera(R) Was Effective In Treating ADHD In Children And Adolescents With ADHD And Reading Disorders 10/27/2006
More...
|
Study: Some Preschoolers Can Use Ritalin 10/23/2006
More...
|
Concerta Safe For Children With ADHD And Epilepsy 10/12/2006
More...
|
FDA Issues Approvable Letter For New River Pharmaceuticals Inc. (NRPH) And Shire Pharmaceuticals (SHPGY)'s NRP104 For The Treatment Of ADHD 10/9/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: ADDERALL XR(R) Paragraph IV Notice Received 10/3/2006
More...
|
Attention Deficit Treatment A Family Affair 9/28/2006
More...
|
A Smoking Gun For ADHD 9/19/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) Meets Enrollment In NRP104 Adult Phase III Study 9/12/2006
More...
|
Cortex Pharmaceuticals, Inc. (COR) Submits Complete Response To FDA To Address Clinical Hold On CX717 9/11/2006
More...
|
Cortex Pharmaceuticals, Inc. (COR) To Present Phase II Data From Adult ADHD Study At AACAP Meeting 9/5/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces NDA Submission Of Guanfacine Extended Release For The Treatment Of ADHD In Children And Adolescents 8/24/2006
More...
|
ADHD Drugs To Have Stronger Warning; Include Novartis International AG (NVS)'s Dexedrine And GlaxoSmithKline Biologicals (GSK)'s Ritalin 8/22/2006
More...
|
GlaxoSmithKline (GSK) Adds Heart Warning To ADHD Drug, Follows FDA 8/21/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) And Barr Laboratories (BRL) Settle All Pending Litigation Concerning ADDERALL XR(R) And Enter Into Development And License Agreement 8/15/2006
More...
|
Boston Life Sciences (BLSI) Announces The Issuance Of A U.S. Patent Licensed To BLSI By Harvard et al That Covers Methods For The Diagnosis And Monitoring Of ADHD 8/11/2006
More...
|
Cephalon, Inc. (CEPH) Receives Non-Approvable Letter On SPARLON(TM); To Drop Drug Development 8/10/2006
More...
|
Shire plc Announces Filing Of SPD465 For The Treatment Of Adult ADHD 7/21/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY)'s DAYTRANA(TM), First Transdermal Medication For Treatment Of Attention Deficit Hyperactivity Disorder (ADHD) In Children, Now Available In Pharmacies 6/29/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Abuse Liability Study Results Of Lisdexamfetamine Dimesylate (NRP104) Presented At College On Problems Of Drug Dependence 6/28/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) To Host Conference Call On A01, A02 And A03 Clinical Abuse Liability Studies Of NRP104 6/23/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) Provides Detail On A02 Clinical Abuse Liability Study Of NRP104 6/21/2006
More...
|
Omega-3 Fish Oil "Can Treat ADHD" 6/20/2006
More...
|
Pine Bark Extract Could Calm ADHD Kids, Says Study 6/19/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) Provides Detail On A01 Clinical Abuse Liability Study And Announces Results From A03 Study 6/19/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) To Present Results From NRP104 Abuse Liability Studies 6/14/2006
More...
|
Avoid ADHD Drugs, Canada Tells Heart Patients 5/26/2006
More...
|
Mixed Amphetamine Salts Extended Release Improves Information Processing In Adults With ADHD 5/25/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) Release: Positive NRP104 Study Results Presented At American Psychiatric Association Meeting 5/25/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (Methylphenidate Transdermal System) Wear Time 5/25/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Positive Study Results For NRP104 Presented At American Psychiatric Association Meeting 5/24/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Positive Study Results For DAYTRANA(TM) (Methylphenidate Transdermal System) Presented At A Major Medical Meeting 5/24/2006
More...
|
Eli Lilly and Company (LLY) Release: Study Suggests Atomoxetine Significantly Improved Functioning In Children With Both ADHD And Anxiety Disorders 5/24/2006
More...
|
UCB Group (UCBJF.PK) Completes Mutual Recognition Procedure For Equasym(TM) XL 5/24/2006
More...
|
Mixed Amphetamine Salts Extended Release Improves Speed And Accuracy Of Information Processing In Adults With ADHD Reports The Washington Neuropsychological Institute 5/24/2006
More...
|
Mixed Amphetamine Salts Most Effective In The Treatment Of ADHD in Youths Reports The SUNY Upstate Medical Center 5/24/2006
More...
|
New River Pharmaceuticals Inc. (NRPH) Initiates Pivotal Phase III Trial Of NRP104 For Adult ADHD 5/23/2006
More...
|
Do ADHD Drugs Stunt Kids' Growth? 5/2/2006
More...
|
Cephalon, Inc. (CEPH) Provides Update On Regulatory Status Of SPARLON(TM); FDA Delays Decision 4/25/2006
More...
|
Cephalon, Inc. (CEPH) Says Sparlon Skin Rash Not SJ Syndrome 4/19/2006
More...
|
Noven Pharmaceuticals Inc. (NOVN) And Shire Pharmaceuticals Group plc (SHPGY) Announce FDA Approval Of Daytrana(TM) Methylphenidate Transdermal System; First Attention Deficit Patch 4/7/2006
More...
|
Alfresa Pharma Corporation And Tanabe Seiyaku Company To Collaborate In Development And Sales Of Narcolepsy Drug Modafinil 4/5/2006
More...
|
Australian Students In Hospital After Taking Drug 3/31/2006
More...
|
ADHD Teens Calmed By Omega Oils 3/28/2006
More...
|
Cephalon, Inc. (CEPH) Release: FDA Advisory Committee Recommends Against Approval Of SPARLON(TM) For Attention Deficit/Hyperactivity Disorder In Children And Adolescents 3/24/2006
More...
|
Advisers Reject Strong ADHD Warnings 3/23/2006
More...
|
US FDA Staff Questions Cephalon, Inc. (CEPH) Drug For ADHD; Cephalon Announces Conference Call Invitation 3/22/2006
More...
|
Panel Seeks New Warnings For ADHD Drugs 3/22/2006
More...
|
Medco Health Solutions, Inc. Release: New Data Shows Adults Continue To Outpace Children In Growth Of ADHD Medication Use 3/21/2006
More...
|
Specialty Pharmaceuticals Division Of McNeil-PPC, Inc. Releases CONCERTA(R) (methylphenidate HCl) Extended-release Tablets ADHD Treatment Data In Preparation For FDA Pediatric Advisory Committee Meeting 3/20/2006
More...
|
Cephalon, Inc. (CEPH) Shares Slip On Concerns FDA Suicide Risk Memo May Affect Sparlon Advisory Panel 3/16/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Status Of Ongoing FDA Review Of NDA For DAYTRANA(TM) For The Treatment Of ADHD; Daytrana Declared In Class I Resubmission 3/10/2006
More...
|
Cortex Pharmaceuticals, Inc. (COR) Reports Positive Results With CX717 On The Primary Outcome Measure In Adult ADHD Study 3/6/2006
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Says Wants More Study On ADHD Side Effects 2/10/2006
More...
|
FDA Reports 51 Deaths Of Attention Drug Patients; Includes Shire Pharmaceuticals Group plc (SHPGY)'s Adderall And Novartis Pharma AG (NVS)'s Ritalin 2/9/2006
More...
|
New Treatments For Attention Disorders To Hit The Market In 2006 1/12/2006
More...
|
Australia Won't Investigate ADHD Drugs 1/5/2006
More...
|
Shire Pharmaceuticals (SHPGY) Receives FDA Approvable Letter For DAYTRANA(TM) For The Treatment Of ADHD 12/27/2005
More...
|
Noven Pharmaceuticals Inc. (NOVN) To Commence Manufacture Of Daytrana(TM) Methylphenidate Transdermal System 12/14/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces New River Pharmaceuticals Inc. (NRPH) Filing Of NRP104 12/8/2005
More...
|
New River Pharmaceuticals Inc. (NRPH) Files New Drug Application On NRP104 For Treatment Of Pediatric ADHD 12/7/2005
More...
|
FDA Committee Backs Noven Pharmaceuticals Inc. (NOVN)'s And Shire Pharmaceuticals (SHPGY)' Skin Patch For Hyperactivity In Children 12/5/2005
More...
|
Cephalon, Inc. (CEPH) Release: Pediatrics Publishes Pivotal Study Showing SPARLON(TM) Significantly Improves ADHD Symptoms In Children And Adolescents 12/5/2005
More...
|
FDA Staffer Now Says Noven Pharmaceuticals Inc. (NOVN) And Shire Pharmaceuticals (SHPGY) ADHD Patch Approvable; Reversing Earlier Opinion; Noven Trading Halted Ahead Of FDA Meeting On Patch 12/2/2005
More...
|
US FDA Staff Says Noven Pharmaceuticals Inc. (NOVN) And Shire Pharmaceuticals (SHPGY) ADHD Patch Cannot Be Sold Safely 12/1/2005
More...
|
Gene, Birth Weight Linked To Antisocial Behavior 11/23/2005
More...
|
Ritalin May Ease Autism-Linked Hyperactivity 11/10/2005
More...
|
Gene May Spur ADHD Antisocial Behaviors 11/10/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Positive Results Of Two-Year Study Of ADDERALL XR(R) In The Treatment Of Adult ADHD 11/10/2005
More...
|
Washington Neuropsychological Institute Release: ADDERALL XR(R) Significantly Improves Driving Performance And Attention In Young Adults With ADHD 11/9/2005
More...
|
Hyperactivity Drug May Help Autism 11/8/2005
More...
|
Common Drug Cures Learning Disability 11/8/2005
More...
|
Shire Pharmaceuticals (SHPGY) Announces Preliminary Results Of Largest Adult ADHD Trial Conducted To Date 10/28/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Developmental Methylphenidate Patch Scheduled For FDA Advisory Committee Review 10/27/2005
More...
|
FDA Withdraws Approval For ADD Drug 10/25/2005
More...
|
Abbott Laboratories (ABT) Discontinued ADHD Drug Too Risky Says FDA 10/24/2005
More...
|
Cephalon, Inc. (CEPH) ADHD Drug Takes Step Closer To Approval 10/21/2005
More...
|
Gene May Be Linked To Tourette's Syndrome 10/14/2005
More...
|
ADDERALL XR(R) - Shire Pharmaceuticals Group plc (SHPGY) Submits Citizen Petition On Efficacy And Safety Concerns With The FDA 10/13/2005
More...
|
Lexicor Medical Technologies, Inc. Release: Multi-Center Study Evaluates Use Of NeuroLex Indicator Report Service(SM) In ADHD Assessment 10/6/2005
More...
|
Lexicor Medical Technologies, Inc. Release: Multi-Center Study Evaluates Use Of NeuroLex Indicator Report Service In ADHD Assessment 10/5/2005
More...
|
Eli Lilly and Company (LLY) Adds Suicide Risk To Strattera 9/29/2005
More...
|
Lexicor Medical Technologies, Inc. Release: Multi-Center Study Evaluates Use Of NeuroLex Indicator Report Service In ADHD Assessment 9/28/2005
More...
|
McNeil Consumer & Specialty Pharmaceuticals (JNJ) Announces Agreement With Cephalon, Inc. (CEPH) To Co-Promote Modafinil For Attention-Deficit/Hyperactivity Disorder 9/1/2005
More...
|
ALLIANT Pharmaceuticals, Inc. To Conduct Largest U.S. ADHD Clinical Survey 8/10/2005
More...
|
Children Of Smokers Have More Attention Deficit 8/1/2005
More...
|
Cortex Pharmaceuticals, Inc. (COR) Commences Enrollment In Two Additional Phase IIa Studies With AMPAKINE CX717; ADHD And Alzheimer's Disease Studies Are Underway 7/28/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) And Noven Pharmaceuticals Inc. (NOVN) Resubmitted NDA For MTS, A Candidate Treatment For Pediatric ADHD Patients 7/26/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: FDA Expands Indication For ADDERALL XR(R) (CII) Confirming Safety And Efficacy In Adolescents 7/22/2005
More...
|
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Notice Of A U.S. Patent Allowance For SPI-339, A Potential Drug For Attention Deficit And Hyperactivity Disorder 7/20/2005
More...
|
Researchers Urge Caution On Ritalin-Cancer Link Finding 7/5/2005
More...
|
FDA Told To Delay ADHD Drug Labeling Changes 7/1/2005
More...
|
FDA Gets Tough On ADHD Drugs; New Labels That Highlight Psychiatric Side Effects Will Be Ordered For One Class Of Medicines 6/30/2005
More...
|
McNeil Consumer & Specialty Pharmaceuticals (JNJ) Data Shows That ADHD Patients On CONCERTA(R) Are More Likely To Continue With Long-Term Therapy Than Those On Other Methylphenidate Drugs 6/28/2005
More...
|
IMS Health (RX) Release: New IMS Offerings Support Market Assessment, Product Valuation, Pricing & Reimbursement, Business Development 6/15/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: ADDERALL XR(R) Paragraph IV Notice Update 6/7/2005
More...
|
Novartis Pharmaceuticals Corporation (NVS) And Celgene Corporation (CELG) Release: FDA Grants Approval To Market Focalin XR(TM) For The Treatment Of ADHD In Adults, Adolescents And Children 5/27/2005
More...
|
Johnson & Johnson (JNJ) Sees 10 To 13 New Drugs Approved By 2007 5/27/2005
More...
|
Video Feed: Novartis Pharmaceuticals Corporation's (NVS) FOCALIN XR (TM) Approved For Treatment Of ADHD In Adults, Adolescents And Children 5/27/2005
More...
|
New River Pharmaceuticals Inc. (NRPH) Release: NRP104 Meets Primary And Secondary Endpoints In Phase 3 Study 5/23/2005
More...
|
Eli Lilly and Company (LLY) Release: Non-stimulant Strattera More Widely Available For Attention- Deficit/Hyperactivity Disorder In Children And Adolescents In Europe 5/18/2005
More...
|
Eli Lilly and Company (LLY) Profit Up, But Drug Sales Down 4/19/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Release: Court Sets New Trial Date For IMPAX Laboratories, Inc. (IPXL) Cases: February 2006 4/15/2005
More...
|
Noven Pharmaceuticals Inc. (NOVN) And Shire Pharmaceuticals Group plc (SHPGY) Announce Positive Clinical Data For Transdermal ADHD Treatment 4/6/2005
More...
|
Abbott Says Withdrawing Attention Deficit Drug 3/28/2005
More...
|
Group Calls For Ban Of Abbott Laboratories' (ABT) Attention Deficit Disorder Drug 3/24/2005
More...
|
Saegis Pharmaceuticals, Inc. Initiates Phase II Clinical Trial Of SGS742 In Adult ADHD 3/22/2005
More...
|
Strattera Safety Helped By DNA Testing, According To FDA Approved Product Labeling Notes Genelex Corporation Founder, Howard Coleman 3/9/2005
More...
|
New River Pharmaceuticals Inc. (NRPH) Release: NRP104 Meets Primary Endpoint In Phase 2 Study 3/2/2005
More...
|
FDA Issues Alert On ADHD Drug Adderall 2/11/2005
More...
|
Shire Pharmaceuticals Group plc (SHPGY) Announces Suspension Of ADDERALL XR(R) Sales In Canada 2/10/2005
More...
|
New River Pharmaceuticals Inc. (NRPH) Provides Update On Clinical Trials And Pipeline 2/9/2005
More...
|
Fujisawa Pharmaceutical Co., Ltd. And Carlsson Research AB Conclude Licensing Agreement For Antipsychotic Agent ACR-16 2/8/2005
More...
|
Liver Alert On Hyperactivity Drug 2/3/2005
More...
|
Neurognostics, Inc. Receives 510(k) Clearance For MindState® fDAD® Used For Acquisition Of fMRI Data 2/1/2005
More...
|
Shire Laboratories (SHPGY) And New River Pharmaceuticals Inc. (NRPH) Announce Collaboration On Phase III ADHD Drug Candidate; Shire To Pay Up To $500 Millon In Drug Deal 1/31/2005
More...
|
First Biological Test For ADHD Unveiled 1/17/2005
More...
|
Shire Pharmaceuticals Group PLC (SHPGY) Signs Non-Binding Agreement For New ADHD Phase III Compound 1/3/2005
More...
|
Cephalon (CEPH) Files Application For Marketing Approval Of New Modafinil Formulation For The Treatment Of Children And Adolescents With Attention-Deficit/Hyperactivity Disorder 12/21/2004
More...
|
Iron Supplements May Help ADHD Children 12/16/2004
More...
|
ADDERALL XR(R) - Additional Paragraph IV Notice Received From IMPAX Laboratories, Inc. (IPXL) For Lower Strengths 12/7/2004
More...
|
Shire Pharmaceuticals Group PLC (SHPGY) Release: ADDERALL XR(R) - Paragraph IV Notice Received 12/2/2004
More...
|
St. Jude Children's Research Hospital Release: Methylphenidate Improves Attention, Behavior Of Children Surviving Acute Lymphoblastic Leukemia, Brain Tumors 12/2/2004
More...
|
Brain Abnormality Linked To Hyperactivity Disorder 11/30/2004
More...
|
Brain Abnormality Linked To Hyperactivity Disorder 11/29/2004
More...
|
McNeil Consumer & Specialty Pharmaceuticals (JNJ) Release: Children With ADHD Experience Greater Reduction Of Behavioral Symptoms With Higher Doses Of CONCERTA vs. Methylphenidate, Study Shows 11/22/2004
More...
|
Washington Neuropsychological Institute Release: Preliminary Data Suggest ADDERALL XR(R) CII Significantly Improved Simulated Driving Performance In Young Adults With ADHD 11/19/2004
More...
|
Shire Pharmaceuticals Group PLC (SHPGY) Release: ADDERALL XR (R) Gets 6 Months Pediatric Exclusivity 10/28/2004
More...
|
McNeil Consumer & Specialty Pharmaceuticals (JNJ) Release: FDA Approves Use Of CONCERTA 72 Mg For Treatment Of Attention Deficit Hyperactivity Disorder 10/26/2004
More...
|
Celgene Corporation (CELG) Release: Focalin XR(TM) Clinical Studies Suggest Investigational Once-Daily ADHD Treatment Is Safe And Effective In Both Children And Adults 10/25/2004
More...
|
Novartis Pharmaceuticals Corporation (NVS) Release: New Studies Suggest Investigational Once-Daily ADHD Treatment Is Safe And Effective In Both Children And Adults 10/25/2004
More...
|
Shire Pharmaceuticals Group PLC (SHPGY) Release: Long-Term Study Demonstrated ADDERALL XR(R) (CII) Is An Effective Option To Treat Adolescents With ADHD 10/21/2004
More...
|
Children's Hospital of Philadelphia Release: Chronic Opiate Use May Raise Vulnerability To Stress -- Animal Study Sheds Light On Effects Of Hospital Drugs -- 9/28/2004
More...
|
Alliant Pharmaceuticals, Inc. Release: Making ADHD Meds Easier To Swallow 9/7/2004
More...
|
Able Laboratories (ABRX) Receives FDA Approval For Dextroamphetamine Sulfate Extended-Release Capsules 5mg CII, 10mg CII And 15mg CII 8/25/2004
More...
|
Cephalon (CEPH) Announces Positive Results With A New Modafinil Formulation For The Treatment Of Children With Attention Deficit Hyperactivity Disorder 8/19/2004
More...
|
Brain Anti-Anxiety Switch Found 8/19/2004
More...
|
Shire Pharmaceuticals Group PLC (SHPGY) Release: US FDA Approves Adderall XR(R) To Treat Adults 8/12/2004
More...
|
Host Of ABC's Extreme Makeover: Home Edition, Ty Pennington, To Participate In Experts On Call Program; Nation's Top Experts To Answer Questions About Attention-Deficit/Hyperactivity Disorder 8/6/2004
More...
|
Noven Pharmaceuticals Inc. (NOVN) Provides MethyPatch Development Update; Additional Clinical Studies To Proceed As Planned 6/16/2004
More...
|
Noven Pharmaceuticals Inc. (NOVN) And Shire Pharmaceuticals Group PLC (SHPGY) Sign Development Agreement For New ADHD Patch 6/16/2004
More...
|
Eli Lilly and Company (LLY) Release: First Non-Stimulant ADHD Medication Available In The United Kingdom 6/3/2004
More...
|
Medco Study Reveals Pediatric Spending Spike On Drugs To Treat Behavioral Problems 5/17/2004
More...
|
The Assessment Center Introduces DataLex AD/HD Report To Accurately Measure Attention Deficit Disorder 5/12/2004
More...
|
Ritalin May Improve Parkinson's Symptoms, OHSU Study Says 5/7/2004
More...
|